Reteplase

From WikiProjectMed
Jump to navigation Jump to search
Reteplase
Names
Trade namesRetavase, Retefuse, Rapilysin, Mirel, others
Clinical data
Drug classTissue plasminogen activator[1]
Main usesHeart attacks[1]
Side effectsBleeding, allergic reaction[1]
External links
AHFS/Drugs.comMonograph
US NLMReteplase
Legal
License data
Chemical and physical data
FormulaC1736H2671N499O522S22
Molar mass39589.75 g·mol−1
  (verify)

Reteplase, trade names include Retavase, is a thrombolytic medication primarily used to treat heart attacks.[1] It may also be used to treat certain pulmonary embolisms.[1] It is given by injection into a vein.[1]

Common side effects include bleeding.[2] Other side effects may include allergic reactions and cholesterol embolism.[1] Safety in pregnancy is unclear.[3] It is a recombinant protein form of the human tissue plasminogen activator.[1]

Reteplase was approved for medical use in the United States and Europe in 1996.[2][4] In the United States it costs about 3,600 USD per dose as of 2021.[5]

Medical uses

It should be used with 12 hours of the start of a heart attack.[4]

Mechanism of action

Reteplase is similar to recombinant human tissue plasminogen activator (alteplase), but the modifications give reteplase a longer half-life of 13–16 minutes. Reteplase also binds fibrin with lower affinity than alteplase, improving its ability to penetrate into clots.

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 "Reteplase Monograph for Professionals". Drugs.com. Retrieved 16 October 2021.
  2. 2.0 2.1 "DailyMed - RETAVASE- reteplase kit". dailymed.nlm.nih.gov. Retrieved 16 October 2021.
  3. "Reteplase Use During Pregnancy". Drugs.com. Retrieved 16 October 2021.
  4. 4.0 4.1 "Rapilysin". Retrieved 16 October 2021.
  5. "Retavase Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 16 October 2021.

External links

External sites:
Identifiers: